Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Free Report) have been assigned an average rating of “Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $12.20.
A number of equities analysts have commented on RANI shares. HC Wainwright increased their target price on Rani Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday. Wedbush reissued an “outperform” rating and set a $8.00 price target on shares of Rani Therapeutics in a research report on Tuesday, February 6th. Canaccord Genuity Group dropped their price target on Rani Therapeutics from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 27th. Finally, BTIG Research boosted their price objective on shares of Rani Therapeutics from $7.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday.
Get Our Latest Analysis on Rani Therapeutics
Rani Therapeutics Stock Down 5.2 %
Rani Therapeutics (NASDAQ:RANI – Get Free Report) last announced its quarterly earnings data on Wednesday, March 20th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04. On average, equities analysts expect that Rani Therapeutics will post -0.94 earnings per share for the current year.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Featured Stories
- Five stocks we like better than Rani Therapeutics
- Business Services Stocks Investing
- Roblox: The Bottom Just Fell Out of the Metaverse
- Buy P&G Now, Before It Sets A New All-Time High
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- What is the Shanghai Stock Exchange Composite Index?
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.